News for Lixte Biotechnology Holdings, Inc. (LIXT)

PASADENA, Calif., July 16, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (”œLIXTE” or the ”œCompany”) ( LIXT and LIXTW), a clinical stage

Lixte Biotechnology Holdings, Inc. (LIXT) has successfully met the Nasdaq's equity requirement, as confirmed by a recent notification from the Nasdaq Hearings P

Successfully raised $6.5 million through combined offerings, meeting Nasdaq compliance. Regained compliance with Nasdaq Capital Market listing requireme

Minnesota-based Nuwellis, Inc. (NUWE) is up over 147 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Canada-based Above Food Ingredients Inc. (ABVE) is up over 115 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

New York, NY, July 09, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the closing of a $1.5 million registered direct offering for Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), in which it served as the exclusive placement agent.

Article Indicates that Inhibition of PP2A Enhances Immunotherapy Responsewith LIXTE's Proprietary Compound LB100 PASADENA, Calif., July 09, 2025 (GLOBE NEWSW

PASADENA, CALIF, July 08, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the 'Company”), a clinical stage pharmaceutical company, today announced the closing of a registered direct offering with accredited investors for the purchase and sale of approximately $1.5 million of shares of Common Stock (or Pre-Funded Warrants).

Shares of Apogee Therapeutics, Inc. APGE rose sharply in today's pre-market trading after the company disclosed positive 16-week data from Phase 2 APEX clinical...

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 200 points on Thursday. Following the market opening Thursday, the Dow trade...

Lixte Biotechnology Holdings (LIXT) secures $5 million in a private placement. The company receives immediate access to $4 million, with $1 million cont

PASADENA, CALIF, July 01, 2025 (GLOBE NEWSWIRE) -- Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) (the 'Company”), a clinical stage pharmaceutical company, today announced that, on June 30, 2025 intraday, it entered into a definitive agreement with accredited investors on the purchase and sale of approximately $5.0 million of shares of Common Stock (or Pre-Funded Warrants), Series B Convertible Preferred Stock and Common Warrants. The offering was priced at the market under Nasdaq rules.

**media[581363]**

-- As Published in Two Scientific Journals, Findings Open Potential Biomarker Strategy for Patient Response to LB-100 -- PASADENA, CALIF., March 10, 2025 (GL

-- Lurie Cancer Center Completes Dosing of First Patient with LIXTE's LB-100 in Combination with GSK's Immunotherapy Dostarlimab -- PASADENA, CALIF., Feb. 25

Virginia-based Spire Global, Inc. (SPIR) is down over 52 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading.

Pennsylvania-based Lipella Pharmaceuticals Inc. (LIPO) is up over 62 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.

Shares of Lattice Semiconductor Corporation LSCC rose sharply in pre-market trading after the company reported its fourth-quarter financial results after Monday...

Maryland-based GlycoMimetics, Inc. (GLYC), a biotechnology company is up over 163 percent in Tuesday's pre-market trading. The following are some of the other stocks making big moves in Tuesday's pre-market trading.